What Evommune does

Evommune, Inc. is a clinical-stage biotechnology company founded in 2020 and headquartered in Palo Alto, California, focused on developing differentiated therapies for chronic inflammatory diseases. The company's pipeline is built around two core platforms: EVO756, a selective small molecule antagonist of the Mas-related G-protein coupled receptor X2 (MRGPRX2) being developed as a potential first oral treatment for chronic spontaneous urticaria, atopic dermatitis, and migraine; and EVO301, an anti-serum albumin Fab-associated (SAFA) IL-18 binding protein fusion designed to neutralize IL-18 activity in atopic dermatitis and ulcerative colitis. EVO756 has completed Phase 2a in atopic dermatitis (33% placebo-adjusted EASI improvement at Week 12, 23% IGA 0/1 response) and completed Phase 2b enrollment for chronic spontaneous urticaria with topline data expected Q2 2026, while EVO301 has met its Phase 2a primary endpoint.

The company operates a licensing-based revenue model anchored by a strategic collaboration with Maruho Co., Ltd. covering exclusive development and commercialization of EVO756 in Japan, Greater China, and other key Asian markets, which drove $13.0 million in full-year 2025 revenue (up from $7.0 million in 2024). Evommune has no approved products and is pre-commercial, planning to leverage enterprise field sales upon regulatory approval. The company is publicly traded on NYSE under ticker EVMN following a November 2025 IPO that raised $172.5 million, supplemented by a February 2026 private placement of approximately $125 million, with $307 million in cash and investments reported as of March 31, 2026 — disclosed as sufficient to fund operations through 2028. Leadership includes co-founders Luis Peña (President & CEO, previously co-founder of Dermira acquired by Eli Lilly for $1.1 billion) and Eugene A. Bauer, M.D. (CMO, ex-founder of Dermira and Peplin), along with a management team largely drawn from Kadmon (acquired by Sanofi for $1.9 billion).

Name

Evommune

Legal name

Evommune, Inc.

Website

https://evommune.com

Company type

Public

Founded year

2020

Operating status

Ipo

Headcount range

51–100 employees

Short description

Evommune is a clinical-stage biotechnology company developing oral and biologic therapies for chronic inflammatory diseases via MRGPRX2 antagonism (EVO756) and IL-18BP fusion protein engineering (EVO301), targeting chronic spontaneous urticaria, atopic dermatitis, migraine, and ulcerative colitis. Public on NYSE since November 2025.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals — Inflammatory Disease Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

Keywords

• Clinical-stage biotechnology
• Chronic inflammatory diseases
• MRGPRX2 antagonist therapy
• IL-18BP fusion protein
• Small molecule therapeutics

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Licensing Revenue: Evommune generates revenue through strategic licensing collaborations. The company entered into a strategic collaboration with Maruho Co., Ltd. to exclusively develop and commercialize EVO756 in Japan, Greater China, and other key Asian markets. Revenue for full year 2025 increased to $13.0 million compared to $7.0 million in 2024, driven by this licensing collaboration.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Evommune is a clinical-stage biotechnology company developing differentiated product candidates that target key drivers of chronic inflammatory diseases. Its lead programs are EVO756, an oral small molecule antagonist of the MRGPRX2 receptor being developed for chronic spontaneous urticaria, atopic dermatitis, and migraine, and EVO301, a SAFA IL-18BP fusion protein for atopic dermatitis and ulcerative colitis.

Product overview

Evommune is a clinical-stage biotechnology company advancing a pipeline of differentiated product candidates for chronic inflammatory diseases. The company's portfolio consists of two main investigational therapies: EVO756, an oral small molecule MRGPRX2 antagonist currently in Phase 2 trials for chronic spontaneous urticaria, atopic dermatitis, and migraine; and EVO301, an IL-18BP fusion protein in Phase 2a development for atopic dermatitis and ulcerative colitis.

Differentiator

Problem solved

Functional benefit

Products and services

• EVO756 Investigational oral small molecule antagonist of the MRGPRX2 receptor, being developed for chronic spontaneous urticaria, atopic dermatitis, and migraine by targeting mast cell-mediated inflammation.
• EVO301 Investigational anti-serum albumin Fab-associated (SAFA) IL-18BP fusion protein designed to neutralize aberrantly upregulated IL-18 activity, in development for atopic dermatitis and ulcerative colitis.

Quantifiable outcome

• EVO756 achieved 33% placebo-adjusted improvement in EASI score at Week 12 in Phase 2a atopic dermatitis trial
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Maruho Co., Ltd.coreStrategic or Co-development Partner · 1 March 2024Evommune entered into a strategic collaboration with Maruho Co., Ltd., a globally respected pharmaceutical organization that has developed and commercialized pharmaceuticals in Japan for more than 100 years. The partnership exclusively licenses development and commercialization of EVO756 (MRGPRX2 small molecule antagonist) in Japan, Greater China, and other key Asian markets. The collaboration marks a long-term, multifaceted relationship with potential to accelerate development and expand patient access to EVO756 across Asia.
• Accutar BiotechnologycoreTechnology or Integration · 1 November 2023Evommune and Accutar formed a partnership focused on the discovery of novel small molecule drug candidates targeting the root cause of chronic inflammatory diseases. Accutar employs a sophisticated hybrid approach integrating computational drug design with wet lab validation, overcoming limitations of traditional drug discovery methods. By combining Evommune's deep biological expertise with Accutar's medicinal chemistry engine, the companies aim to develop next-generation therapies for chronic inflammatory diseases.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• AbbVie: Major pharma with Rinvoq (upadacitinib) and Skyrizi competing in atopic dermatitis and ulcerative colitis. Defines the competitive efficacy and safety bar Evommune's oral therapies must exceed.
• Incyte Corporation: Established commercial biotech with multiple approved immunology/inflammation products including ruxolitinib cream (Opzelura) for atopic dermatitis. Competes in the same indications with broader portfolio and commercial infrastructure.
• Eli Lilly: Major pharma with lebrikizumab and OLUMIANT in atopic dermatitis. Acquired Evommune co-founders' prior company (Dermira) and represents a potential strategic acquirer or major competitor depending on data.
• Galderma: Global dermatology-focused pharma with a portfolio of prescription and aesthetic treatments. Represents the established dermatology commercial infrastructure that Evommune may eventually need to partner with or build toward.
• Sanofi: Commercializes Dupixent (with Regeneron), the dominant biologic in atopic dermatitis and CSU. Sets the standard of care against which Evommune's oral MRGPRX2 antagonist will be benchmarked.

Direct peers

• Arcutis Biotherapeutics: Late-stage dermatology-focused biotech commercializing topical therapies for inflammatory skin diseases (atopic dermatitis, seborrheic dermatitis). Closely aligned business model of developing differentiated therapies for chronic inflammatory skin conditions.
• AnaptysBio: Clinical-stage immunology biotech developing antibodies for inflammatory diseases, including atopic dermatitis and other IL-pathway-driven conditions. Directly comparable in mechanism (cytokine modulation) and target indications.
• MoonLake Immunotherapeutics: Clinical-stage biotech developing Nanobody therapy (sonelokimab) for inflammatory skin and joint diseases including atopic dermatitis and hidradenitis suppurativa. Direct competitor in inflammation dermatology with similar stage of development.
• Aclaris Therapeutics: Clinical-stage dermatology and immunology biotech developing therapies for inflammatory skin diseases and immuno-inflammatory conditions. Comparable size, pipeline scope, and target disease areas.

Emerging players

• Connect Biopharma: Clinical-stage inflammation/immunology biotech focused on T-cell-driven inflammatory diseases including atopic dermatitis. Comparable in stage, indication overlap, and therapeutic approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/evommune

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds7 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evommune